Cerus Debt to Equity Ratio 2010-2024 | CERS
Current and historical debt to equity ratio values for Cerus (CERS) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Cerus debt/equity for the three months ending September 30, 2024 was 1.19.
| Cerus Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-09-30 | $0.14B | $0.05B | 2.49 |
| 2024-06-30 | $0.14B | $0.05B | 2.69 |
| 2024-03-31 | $0.14B | $0.05B | 2.77 |
| 2023-12-31 | $0.14B | $0.05B | 2.70 |
| 2023-09-30 | $0.16B | $0.05B | 3.20 |
| 2023-06-30 | $0.15B | $0.05B | 2.85 |
| 2023-03-31 | $0.15B | $0.06B | 2.52 |
| 2022-12-31 | $0.15B | $0.07B | 2.18 |
| 2022-09-30 | $0.14B | $0.07B | 1.91 |
| 2022-06-30 | $0.14B | $0.08B | 1.82 |
| 2022-03-31 | $0.14B | $0.08B | 1.76 |
| 2021-12-31 | $0.15B | $0.09B | 1.77 |
| 2021-09-30 | $0.14B | $0.08B | 1.70 |
| 2021-06-30 | $0.14B | $0.08B | 1.65 |
| 2021-03-31 | $0.13B | $0.09B | 1.38 |
| 2020-12-31 | $0.12B | $0.10B | 1.13 |
| 2020-09-30 | $0.10B | $0.11B | 0.95 |
| 2020-06-30 | $0.10B | $0.12B | 0.88 |
| 2020-03-31 | $0.10B | $0.11B | 0.92 |
| 2019-12-31 | $0.11B | $0.06B | 1.90 |
| 2019-09-30 | $0.10B | $0.06B | 1.70 |
| 2019-06-30 | $0.11B | $0.07B | 1.66 |
| 2019-03-31 | $0.11B | $0.07B | 1.53 |
| 2018-12-31 | $0.08B | $0.09B | 0.93 |
| 2018-09-30 | $0.07B | $0.09B | 0.76 |
| 2018-06-30 | $0.06B | $0.09B | 0.68 |
| 2018-03-31 | $0.06B | $0.09B | 0.69 |
| 2017-12-31 | $0.06B | $0.04B | 1.52 |
| 2017-09-30 | $0.06B | $0.04B | 1.61 |
| 2017-06-30 | $0.04B | $0.04B | 1.13 |
| 2017-03-31 | $0.04B | $0.04B | 1.05 |
| 2016-12-31 | $0.05B | $0.06B | 0.79 |
| 2016-09-30 | $0.04B | $0.07B | 0.61 |
| 2016-06-30 | $0.05B | $0.08B | 0.61 |
| 2016-03-31 | $0.04B | $0.08B | 0.53 |
| 2015-12-31 | $0.05B | $0.10B | 0.47 |
| 2015-09-30 | $0.04B | $0.10B | 0.42 |
| 2015-06-30 | $0.04B | $0.11B | 0.37 |
| 2015-03-31 | $0.03B | $0.11B | 0.30 |
| 2014-12-31 | $0.04B | $0.04B | 0.97 |
| 2014-09-30 | $0.03B | $0.05B | 0.68 |
| 2014-06-30 | $0.03B | $0.04B | 0.74 |
| 2014-03-31 | $0.03B | $0.05B | 0.63 |
| 2013-12-31 | $0.04B | $0.04B | 0.95 |
| 2013-09-30 | $0.04B | $0.04B | 1.23 |
| 2013-06-30 | $0.03B | $0.06B | 0.50 |
| 2013-03-31 | $0.03B | $0.06B | 0.52 |
| 2012-12-31 | $0.03B | $0.02B | 1.56 |
| 2012-09-30 | $0.03B | $0.02B | 1.88 |
| 2012-06-30 | $0.03B | $0.02B | 1.49 |
| 2012-03-31 | $0.03B | $0.02B | 1.69 |
| 2011-12-31 | $0.03B | $0.02B | 1.48 |
| 2011-09-30 | $0.02B | $0.02B | 1.26 |
| 2011-06-30 | $0.03B | $0.01B | 1.95 |
| 2011-03-31 | $0.03B | $0.02B | 1.39 |
| 2010-12-31 | $0.02B | $0.02B | 1.03 |
| 2010-09-30 | $0.02B | $0.01B | 1.61 |
| 2010-06-30 | $0.02B | $0.01B | 1.48 |
| 2010-03-31 | $0.02B | $0.02B | 0.91 |
| 2009-12-31 | $0.01B | $0.02B | 0.61 |
| 2009-09-30 | $0.02B | $0.03B | 0.67 |
| 2009-06-30 | $0.01B | $0.02B | 0.60 |
| 2009-03-31 | $0.01B | $0.03B | 0.43 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.332B | $0.156B |
| Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $204.249B | 26.05 |
| Stryker (SYK) | United States | $146.711B | 33.06 |
| Boston Scientific (BSX) | United States | $132.644B | 38.14 |
| EssilorLuxottica (ESLOY) | France | $112.106B | 0.00 |
| Medtronic (MDT) | Ireland | $110.562B | 16.42 |
| Haleon (HLN) | United Kingdom | $43.682B | 28.38 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.166B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $37.665B | 19.54 |
| ResMed (RMD) | United States | $35.786B | 29.41 |
| Terumo (TRUMY) | Japan | $29.739B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $24.805B | 18.99 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.942B | 13.97 |
| Insulet (PODD) | United States | $18.443B | 73.44 |
| Baxter (BAX) | United States | $16.957B | 11.03 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.065B | 0.00 |
| BellRing Brands (BRBR) | United States | $10.158B | 40.72 |
| Bio-Rad Laboratories (BIO) | United States | $9.320B | 31.68 |
| Demant (WILYY) | Denmark | $8.342B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.294B | 14.62 |
| TG Therapeutics (TGTX) | United States | $5.459B | 0.00 |
| Haemonetics (HAE) | United States | $4.297B | 20.97 |
| Prestige Consumer Healthcare (PBH) | United States | $4.192B | 20.85 |
| ICU Medical (ICUI) | United States | $4.125B | 39.27 |
| Perrigo (PRGO) | Ireland | $3.830B | 11.27 |
| Envista Holdings (NVST) | United States | $3.697B | 27.54 |
| Neogen (NEOG) | United States | $3.246B | 37.45 |
| Agios Pharmaceuticals (AGIO) | United States | $3.175B | 0.00 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.841B | 18.22 |
| QuidelOrtho (QDEL) | United States | $2.700B | 17.38 |
| LeMaitre Vascular (LMAT) | United States | $2.428B | 59.00 |
| Warby Parker (WRBY) | United States | $2.349B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.913B | 33.48 |
| AtriCure (ATRC) | United States | $1.742B | 0.00 |
| InMode (INMD) | Israel | $1.597B | 9.61 |
| AdaptHealth (AHCO) | United States | $1.326B | 9.48 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.318B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.267B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.207B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.962B | 16.96 |
| Owens & Minor (OMI) | United States | $0.952B | 7.44 |
| CeriBell (CBLL) | United States | $0.943B | 0.00 |
| National Vision Holdings (EYE) | United States | $0.918B | 30.68 |
| Capricor Therapeutics (CAPR) | United States | $0.847B | 0.00 |
| Evolus (EOLS) | United States | $0.798B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.684B | 30.25 |
| Omeros (OMER) | United States | $0.632B | 0.00 |
| Surmodics (SRDX) | United States | $0.563B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.533B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.522B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.468B | 0.00 |
| Quanterix (QTRX) | United States | $0.451B | 0.00 |
| ZimVie (ZIMV) | United States | $0.391B | 32.95 |
| Valneva SE (VALN) | France | $0.360B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.341B | 32.41 |
| Sanara MedTech (SMTI) | United States | $0.330B | 0.00 |
| Biote (BTMD) | United States | $0.325B | 7.12 |
| OraSure Technologies (OSUR) | United States | $0.289B | 19.40 |
| Zynex (ZYXI) | United States | $0.263B | 55.07 |
| Aurora Cannabis (ACB) | Canada | $0.238B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.225B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.221B | 15.29 |
| High Tide (HITI) | Canada | $0.213B | 88.33 |
| MacroGenics (MGNX) | United States | $0.203B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.188B | 2.64 |
| Brainsway (BWAY) | Israel | $0.167B | 100.00 |
| Organigram Holdings (OGI) | Canada | $0.166B | 0.00 |
| Jin Medical (ZJYL) | China | $0.164B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.160B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.149B | 18.67 |
| TriSalus Life Sciences (TLSI) | United States | $0.138B | 0.00 |
| Fonar (FONR) | United States | $0.104B | 11.74 |
| Quipt Home Medical (QIPT) | United States | $0.104B | 0.00 |
| Veru (VERU) | United States | $0.099B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.094B | 23.40 |
| Ayr Wellness (AYRWF) | United States | $0.077B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.073B | 37.50 |
| Exagen (XGN) | United States | $0.072B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.065B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.063B | 0.00 |
| InterCure (INCR) | Israel | $0.062B | 0.00 |
| Modular Medical (MODD) | United States | $0.058B | 0.00 |
| MariMed (MRMD) | United States | $0.057B | 0.00 |
| Apyx Medical (APYX) | United States | $0.054B | 0.00 |
| Safety Shot (SHOT) | United States | $0.051B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.050B | 0.00 |
| ImmuCell (ICCC) | United States | $0.033B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.028B | 0.00 |
| Flora Growth (FLGC) | United States | $0.019B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.018B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.016B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.006B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.002B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 12.83 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |